Schroetter Syndrome: Effort-Induced Upper Extremity DVT Explained
Indunil Karunarathna, Founder of Uva Clinical Research Lab (UCRL), posted on LinkedIn:
”Schroetter Syndrome Effort Induced Upper Extremity Deep Vein Thrombosis
Paget-Schroetter syndrome (PSS), also known as “effort thrombosis,” represents a primary form of upper extremity deep vein thrombosis (UEDVT) typically arising in young, healthy, and active individuals following strenuous or repetitive upper limb exertion.
Recognized as the venous subtype of thoracic outlet syndrome (TOS), PSS occurs due to mechanical compression of the subclavian vein within the costoclavicular space, often potentiated by structural anomalies such as cervical ribs, hypertrophied scalene muscles, or aberrant ligamentous insertions. The pathophysiology integrates Virchow’s triad, with endothelial trauma, venous stasis, and hypercoagulability converging to precipitate thrombosis.
Clinically, PSS presents with sudden upper extremity swelling, pain, heaviness, and cyanosis, often following athletic or occupational activity. Diagnosis requires high clinical suspicion and confirmation with duplex ultrasonography, venography, or advanced cross-sectional imaging, while laboratory investigations may identify concomitant thrombophilic disorders.
Management strategies emphasize multimodal therapy: immediate anticoagulation, catheter-directed thrombolysis (CDT) or pharmacomechanical thrombectomy for clot clearance, and surgical thoracic outlet decompression to correct the underlying anatomical cause. Long-term outcomes are optimized by interdisciplinary collaboration involving vascular surgeons, radiologists, internists, and rehabilitation specialists.
Despite advances in endovascular and surgical techniques, controversies remain regarding timing of decompression, duration of anticoagulation, and management of chronic venous occlusion. With appropriate treatment, recanalization rates of 75–90% are achievable, preventing long-term complications such as recurrent thrombosis, pulmonary embolism, and postthrombotic syndrome.
Future research should focus on refining minimally invasive strategies, optimizing patient selection for surgical intervention, and developing preventive approaches for high-risk athletic populations.”
Read the full article here.
Author: Indunil Karunarathna

Stay updated with Hemostasis Today.
-
Jul 13, 2026, 20:17Julia R. Coleman: Fantastic First Day at ISTH 2026
-
Jul 13, 2026, 20:11Ruah Alyamany: Combination Therapy Improves Quality of Life in ITP
-
Jul 13, 2026, 19:47Brian O Mahony: Two-Year Results of BBM-H901 Gene Therapy Presented at ISTH 2026
-
Jul 13, 2026, 19:37Sara Zalghout: Connecting With Colleagues From All Over the World at ISTH 2026
-
Jul 13, 2026, 18:54Alfonso J. Tafur: New Evidence on Perioperative Anticoagulation in Cancer at ISTH 2026
-
Jul 13, 2026, 18:42Jessica Garcia: Thrombin Generation in Type 3 VWD With an Inhibitor on Emicizumab
-
Jul 13, 2026, 18:19Fionnuala Ní Áinle: High-Quality Evidence for DVT Diagnosis in Pregnancy at ISTH 2026
-
Jul 13, 2026, 17:39Pascal Boulanger: Send a Postcard to Your Lab Staff From ISTH 2026
-
Jul 13, 2026, 17:21Stefano Navarro: Presenting Our Recently Published Article at ISTH 2026